Gemcitabine radiosensitization for rectal cancer: step forward or dance step?
O'Neil
Bert H
BH
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. bert_oneil@med.unc.edu
Tepper
Joel E
JE
D017322:Clinical Trials, Phase II as Topic; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D011300:Preoperative Care; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D000093542:Gemcitabine
D011838:Radiation-Sensitizing Agents; D003841:Deoxycytidine; D000093542:Gemcitabine